ArticleJPGN reports2026
Juvenile polyposis in a SMAD4-mutated child: A call for early surveillance.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Juvenile polyposis in a SMAD4-mutated child: A call for early surveillance.JPGN reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 10-year-old boy with hereditary hemorrhagic telangiectasia (HHT) and a family history of SMAD4-related juvenile polyposis syndrome (JPS), presenting with hypoferritinaemia unresponsive to oral supplementation. Endoscopic evaluation revealed multiple gastrointestinal polyps, including duodenal, gastric, and colonic lesions. Histology confirmed a tubular adenoma with low-grade dysplasia. Genetic analysis identified a heterozygous pathogenic SMAD4 variant (c.1549_1550del), confirming the diagnosis of JPS. This case illustrates the early onset and clinical complexity of SMAD4-associated JPS-HHT overlap syndrome. It highlights the need for earlier, individualized screening in at-risk children. Timely diagnosis and endoscopic monitoring can prevent severe complications, reduce the need for major surgery, and improve outcomes. Emerging therapies, such as Sirolimus, may offer additional benefit in managing polyp burden and anemia. Familial cascade testing was pivotal in identifying the mutation and guiding management. This report reinforces the importance of early personalized surveillance and a multidisciplinary approach in children with SMAD4 mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.